Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
03:41pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Denali Therapeutics (
DNLI
–
Research Report
), with a price target of
$28.00
. The company’s shares clo
Alector (ALEC) Gets a Buy Rating from Morgan Stanley
03:40pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Alector (ALEC), with a price target of $29.00. The company's
Analysts Have Conflicting Sentiments on These Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Genmab (GMAB) and Mylan (MYL)
03:39pm, Wednesday, 15'th Apr 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rhythm Pharmaceuticals (RYTM), Genmab (GMAB) and Mylan
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on Rhythm Pharmaceuticals (
RYTM
–
Research Report
), Genmab (
GMAB
–
Research Report
) and Mylan (
MY
Insmed (INSM) Gets a Buy Rating from Morgan Stanley
03:38pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Insmed (INSM) today and set a price target of $35.00. The company's shares closed last
Insmed (INSM) Gets a Buy Rating from Morgan Stanley
03:38pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst
Matthew Harrison
maintained a
Buy
rating on Insmed (
INSM
–
Research Report
) today and set a price target of
$35.00
. The company’s shares closed last Wednesday at $17.38.
Moderna (MRNA) Received its Third Buy in a Row
03:38pm, Wednesday, 15'th Apr 2020
After Piper Sandler and Chardan Capital gave Moderna (NASDAQ: MRNA) a Buy rating last month, the company received another Buy, this time from Morgan
Moderna (MRNA) Received its Third Buy in a Row
03:38pm, Wednesday, 15'th Apr 2020
After Piper Sandler and Chardan Capital gave Moderna (NASDAQ: MRNA) a Buy rating last month, the company received another Buy,
Morgan Stanley Sticks to Its Hold Rating for Biohaven Pharmaceutical Holding Co (BHVN)
03:37pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Biohaven Pharmaceutical Holding Co (BHVN) today and set a price target of $46.00. The
Morgan Stanley Sticks to Its Hold Rating for Biohaven Pharmaceutical Holding Co (BHVN)
03:37pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst
Matthew Harrison
maintained a
Hold
rating on Biohaven Pharmaceutical Holding Co (
BHVN
–
Research Report
) today and set a price target of
$46.00
. The company’s shares clos
Morgan Stanley Maintains a Hold Rating on Bluebird Bio (BLUE)
03:35pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Bluebird Bio (BLUE), with a price target of $69.00. The
Morgan Stanley Reaffirms Their Hold Rating on Global Blood Therapeutics (GBT)
03:35pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Global Blood Therapeutics (GBT), with a price target of
Morgan Stanley Reaffirms Their Hold Rating on Global Blood Therapeutics (GBT)
03:35pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Hold
rating on Global Blood Therapeutics (
GBT
–
Research Report
), with a price target of
$70.00
. The company’s shar
Kodiak Sciences (KOD) Received its Third Buy in a Row
03:34pm, Wednesday, 15'th Apr 2020
After J.P. Morgan and BMO Capital gave Kodiak Sciences (NASDAQ: KOD) a Buy rating last month, the company received another Buy, this time from Morgan
Morgan Stanley Maintains Their Hold Rating on Seattle Genetics (SGEN)
03:29pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Seattle Genetics (SGEN) today and set a price target of $111.00. The company's shares
